Sequence: CGGGARKKAAKAARKKAAKAARKKAAKAARKKAAKA
| Experiment Id | EXP001968 |
|---|---|
| Paper | Effective In Vivo Topical Delivery of siRNA and Gene Silencing in Intact Corneal Epithelium Using a |
| Peptide | QN-Palm-POD / siRNA polyplex |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | |
| Rna Concentration | |
| Mixing Ratio | 140:1 (QN-Palm-POD:siRNA) for full complexation; example transfection uses 17.5 µM QN-Palm-POD + 125 nM siRNA. |
| Formulation Format | CPP–siRNA polyplex with covalently attached endosomal disruptor analog |
| Formulation Components | QN-Palm-POD complexed with siRNA (140:1) in PBS. |
| Size Nm | 107.00 |
| Zeta Mv | 14.90 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HCE-S human corneal epithelial cells |
| Animal Model | |
| Administration Route | |
| Output Type | In vitro functional RNA effect (luciferase knockdown) + uptake imaging |
| Output Value | ~50% luciferase knockdown in vitro; >90% cells show siGLO-positive signal. |
| Output Units | |
| Output Notes | siGLO pattern suggests improved endosomal release vs Palm-POD alone (smaller/less defined puncta). |
| Toxicity Notes | MTT: ~80% viability at 9–35 µM; transfections used reduced concentrations to balance complexation and toxicity. |
| Curation Notes |